# INNV earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/INNV) · [Earnings tab](https://www.lopjlb.com/stock/INNV?tab=earnings) Updated: 2026-09-08T09:05:43 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarters, InnovAge transitioned from a turnaround narrative to consistent execution with guidance raises. FY24 established a baseline: $764M revenue (+11%), 17.3% center margin, and $16.5M adj EBITDA. FY25 saw revenue growth sustain at 12-13%, center margin expand to 17.7%, and EBITDA exceed guidance. FY26 accelerated: Q1 revenue +15%, census hit record 7,890, center margin jumped to 21.8% (+320bps QoQ), and adj EBITDA margin reached 9.2% in Q2, prompting two guidance raises. De novo losses narrowed from $18-20M to $3.9M in Q1 FY26, with Orlando delivered and Tampa maturing, though Florida centers flagged at risk in Q3. Technology transformation largely completed: Epic EMR, Oracle financials, and pharmacy in-housing all delivered by Q1 FY26. New strategic vectors emerged in FY26: AI scheduling pilot, participant experience redesign, practice variation reduction, and M&A evaluation. Medicaid redetermination drove enrollment tailwinds but introduced timing uncertainty. Medicare rate pressure (CY2027 blended risk scores, frailty adjuster) and litigation costs (G&A +98% YoY) emerged as FY27 headwinds. State enrollment delays in California persisted but normalized. Cost discipline improved via lower SNF utilization, pharmacy rebates, and in-housing, though external provider costs rose 5% YoY in Q3. ## Latest CallCard · Q3 InnovAge raised FY2026 revenue and EBITDA guidance, citing solid Q3 results, improved margins and ongoing investments, while flagging modest Medicare rate gains and uncertain Medicaid pressures for FY2027. **Guidance:** raised — Guidance was lifted to $950‑$975M revenue and $85‑$90M adjusted EBITDA for FY2026. **Tone:** mgmt 0.7 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks highlighted raised guidance, strong operating execution and confidence in growth initiatives. ### Demand visibility Moderate visibility on future rate environment Management expects Medicare rates to rise 1.5‑2% in FY27, while Medicaid budget pressures may limit rate growth; full outlook to be provided in September. ### Margins / costs Margins improving with stronger cost discipline Center‑level contribution margin rose to 24.2% (up 550bps YoY); external provider costs up 5% YoY, G&A up 98% YoY due to litigation, but cost of care growth moderated. ### Capital allocation Reinvesting in AI, clinical teams, new centers and exploring M&A Investments include AI pilots for scheduling and clinical decision support, expansion of Florida centers, quality measurement development, and evaluation of bolt‑on acquisitions and partnerships. ### Milestones - **AI-driven scheduling pilot** [on_track]: Testing phase to reduce cancellations and improve capacity. - **Florida new centers** [at_risk]: Centers still maturing operationally and financially. - **Outcome‑oriented quality measures** [new]: Early development of functional trajectory and community‑stay metrics. - **Policy modernization advocacy** [new]: Engaging CMS/CMMI to simplify enrollment and expand PACE eligibility. - **De novo center Orlando** [delivered]: Losses reduced to $1.8M after ramp‑up period. - **M&A evaluation** [new]: Assessing bolt‑on opportunities in other states. - **Participant experience analytics** [on_track]: Analyzing disenrollment drivers to improve retention. ### Fears / risks - **Rate pressure**: Potential lower Medicaid rate increases and modest Medicare growth could tighten FY27 margins. - **Litigation liability**: Corporate G&A expenses rose 98% YoY due to litigation costs. - **Cost inflation**: External provider costs up 5% YoY and rising wages increase cost of care. - **Participant retention**: Risk of participants leaving if experience issues are not addressed. - **Regulatory uncertainty**: Future policy changes could affect PACE reimbursement structure. - **De novo center profitability**: New centers may incur losses during ramp‑up periods. - **AI implementation risk**: Adoption and efficacy challenges could limit expected efficiency gains. - **Economic budget pressures**: State budget constraints may limit Medicaid rate growth. ### Key quotes > “Based on our year-to-date operating trends and financial performance, we are once again raising our fiscal year 2026 guidance for revenue and adjusted EBITDA.” > “We are now projecting total revenue for fiscal 2026 in the range of $950 million to $975 million.” ## Quarter one-liners - **2026 Q3:** InnovAge raised FY2026 revenue and EBITDA guidance, citing solid Q3 results, improved margins and ongoing investments, while flagging modest Medicare rate gains and uncertain Medicaid pressures for FY2027. - **2026 Q2:** InnovAge raised FY2026 guidance after achieving 9.2% adj. EBITDA margin in Q2, driven by revenue integrity gains, cost management, and census growth; focusing on participant experience and practice variation to unlock further value. - **2026 Q1:** InnovAge Q1 FY26 beats expectations with 15% revenue growth, doubled adj EBITDA, record census 7,890; reaffirms FY26 guidance but warns against annualizing Q1 due to Medicaid redetermination timing and seasonality. - **2025 Q4:** InnovAge delivered strong FY25 results with revenue up 12%, EBITDA above guidance, and FY26 guidance reflecting continued growth but tempered by Medicaid redetermination headwinds. - **2025 Q3:** InnovAge reaffirmed FY2025 guidance, reporting 13% revenue growth, improved margins and ongoing transformation, while noting policy uncertainty and early-stage de novo center losses. - **2025 Q2:** InnovAge posted modest revenue growth and reaffirmed FY2025 guidance, citing strong PACE demand and Medicaid rate hikes, but flagged enrollment delays and pharmacy integration risks. - **2025 Q1:** InnovAge Q1 FY2025 showed 12% revenue growth, 500% EBITDA increase and strong enrollment momentum, while reaffirming guidance amid modest state audit delays and ongoing cost‑control initiatives. - **2024 Q4:** InnovAge reports FY24 revenue $764M (+11%), center margin 17.3% (+260bps), adj EBITDA $16.5M; guides FY25 revenue $815-865M, adj EBITDA $24-31M, census 7,300-7,750; state enrollment delays persist but improving; de novo losses $18-20M. ## Theme arcs - **Revenue growth** (improving): 11% FY24 → 12-13% FY25 → 15% Q1 FY26; guidance raised twice in FY26 - **Center contribution margin** (improving): 17.3% FY24 → 17.7% Q2 FY25 → 21.8% Q1 FY26 (+320bps QoQ) - **Adj EBITDA margin** (improving): FY24 $16.5M → FY25 above guidance → 9.2% Q2 FY26, exceeding 8-9% target - **Census growth** (improving): Guidance 7,300-7,750 → record 7,890 Q1 FY26 → FY26 guidance 7,900-8,100 - **De novo execution** (improving): Losses $18-20M → $3.9M Q1 FY26; Orlando delivered, Tampa on track but Florida centers at risk Q3 - **Technology transformation** (improving): Epic EMR, Oracle financials, pharmacy in-housing all delivered by Q1 FY26; AI pilot on track Q3 - **Medicaid redetermination impact** (new): First cited Q4 FY25; drove census tailwinds Q1-Q2 FY26 but processing variability persists - **Regulatory & enrollment delays** (stable): California audits and processing delays cited Q1-Q3 FY25; backlog normalization on track Q3 FY25 - **Cost discipline** (improving): External provider PMPM declined (lower SNF, pharmacy rebates, in-housing); wage and pharmacy transition costs offset - **Organizational restructuring** (resolved) ## Guidance path 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:maintained → 2025 Q3:maintained → 2025 Q4:maintained → 2026 Q1:maintained → 2026 Q2:raised → 2026 Q3:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/INNV`